The identification of EGFR as an oncogene has led to the development of anticancer therapeutics directed against EGFR (called “EGFR inhibitors”, EGFRi), including gefitinib [40], erlotinib [41], afatinib, brigatinib, and icotinib [42,43] for lung cancer, and cetuximab for colon cancer. Here, EGFR is linked to malignant colon neoplasm.